Abstracting and Indexing

• PubMed NLM
• Google Scholar
• Semantic Scholar
• Scilit
• CrossRef
• WorldCat
• ResearchGate
• Academic Keys
• DRJI
• Microsoft Academic
• Academia.edu
• OpenAIRE
• Scribd
• Baidu Scholar

Background: Personalised therapy methods have been made possible by molecular profiling, which has transformed cancer diagnosis and treatment. Nevertheless, little information about molecular profiles and their relationship to clinical outcomes is available from tertiary care facilities in eastern India.

Objective: At a tertiary referral centre in Bihar, India, the goal is to assess clinical outcomes and examine the genetic profiles of cancer subjects.

Methods: From January 2022 to December 2023, retrospective observational research was conducted at Katihar Medical College & Hospital in Katihar, Bihar, India. Included were 65 cancer subjects who had molecular profiling. Analysis was done on information on molecular markers, tumour histology, treatment responses, demographics, and survival results.

Results: Among 65 subjects (mean age 58.3 ± 12.7 years, 60% male), lung cancer was the most common (32.3%), followed by breast (24.6%) and colorectal cancer (18.5%). Molecular profiling revealed EGFR mutations in 45.7% of lung cancer subjects, HER2 overexpression in 43.8% of breast cancer subjects, and KRAS mutations in 33.3% of colorectal cancer subjects. Subjects with targetable mutations showed significantly better progression-free survival compared to those without (median 14.2 vs 8.6 months, p<0.05). Overall response rate was 68.4% in the molecularly profiled cohort.

Conclusion: Molecular profiling significantly impacts treatment outcomes in cancer subjects. Our findings from Bihar demonstrate the feasibility and clinical utility of implementing molecular diagnostics in resource limited settings, emphasizing the need for expanded molecular testing capabilities in eastern India.